BACKGROUND: Liver dysfunction in adult hypopituitary patients with GH deficiency (GHD) has been reported and an increased prevalence of nonalcoholic fatty liver disease (NAFLD) has been suggested. OBJECTIVE: The objective of the present study was to elucidate the pathophysiology of the liver in adult hypopituitary patients with GHD. PATIENTS AND METHODS: We recruited 69 consecutive Japanese adult hypopituitary patients with GHD and examined the prevalence of NAFLD by ultrasonography and nonalcoholic steatohepatitis (NASH) by liver biopsy. Patients had been given routine replacement therapy except for GH. We compared these patients with healthy age-, gender-, and BMI-matched controls. We further analyzed the effect of GH replacement therapy on liver function, inflammation and fibrotic markers, and histological changes. RESULTS: The prevalence of NAFLD in hypopituitary patients with GHD was significantly higher than in controls (77 vs 12%, P<0.001). Of 16 patients assessed by liver biopsy, 14 (21%) patients were diagnosed with NASH. GH replacement therapy significantly reduced serum liver enzyme concentrations in the patients and improved the histological changes in the liver concomitant with reduction in fibrotic marker concentrations in patients with NASH. CONCLUSIONS: Adult hypopituitary patients with GHD demonstrated a high NAFLD prevalence. The effect of GH replacement therapy suggests that the NAFLD is predominantly attributable to GHD.
BACKGROUND:Liver dysfunction in adult hypopituitarypatients with GH deficiency (GHD) has been reported and an increased prevalence of nonalcoholic fatty liver disease (NAFLD) has been suggested. OBJECTIVE: The objective of the present study was to elucidate the pathophysiology of the liver in adult hypopituitarypatients with GHD. PATIENTS AND METHODS: We recruited 69 consecutive Japanese adult hypopituitarypatients with GHD and examined the prevalence of NAFLD by ultrasonography and nonalcoholic steatohepatitis (NASH) by liver biopsy. Patients had been given routine replacement therapy except for GH. We compared these patients with healthy age-, gender-, and BMI-matched controls. We further analyzed the effect of GH replacement therapy on liver function, inflammation and fibrotic markers, and histological changes. RESULTS: The prevalence of NAFLD in hypopituitary patients with GHD was significantly higher than in controls (77 vs 12%, P<0.001). Of 16 patients assessed by liver biopsy, 14 (21%) patients were diagnosed with NASH. GH replacement therapy significantly reduced serum liver enzyme concentrations in the patients and improved the histological changes in the liver concomitant with reduction in fibrotic marker concentrations in patients with NASH. CONCLUSIONS:Adult hypopituitarypatients with GHD demonstrated a high NAFLD prevalence. The effect of GH replacement therapy suggests that the NAFLD is predominantly attributable to GHD.
Authors: Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos Journal: J Pediatr Gastroenterol Nutr Date: 2017-02 Impact factor: 2.839
Authors: Shauna S Runchey; Edward J Boyko; George N Ioannou; Kristina M Utzschneider Journal: J Gastroenterol Hepatol Date: 2014-03 Impact factor: 4.029
Authors: Takara L Stanley; Meghan N Feldpausch; Jinhee Oh; Karen L Branch; Hang Lee; Martin Torriani; Steven K Grinspoon Journal: JAMA Date: 2014 Jul 23-30 Impact factor: 56.272
Authors: Jose Cordoba-Chacon; Andre Sarmento-Cabral; Mercedes Del Rio-Moreno; Alberto Diaz-Ruiz; Papasani V Subbaiah; Rhonda D Kineman Journal: Endocrinology Date: 2018-11-01 Impact factor: 4.736
Authors: Takara L Stanley; Lindsay T Fourman; Isabel Zheng; Colin M McClure; Meghan N Feldpausch; Martin Torriani; Kathleen E Corey; Raymond T Chung; Hang Lee; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2021-01-23 Impact factor: 5.958